drugset / Trial / NCT02926586

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

NCT02926586

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine whether Fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with core-binding factor acute myeloid leukemia

Timeline

Start
2017-01-01
Primary completion
2020-08-16
Completion
2024-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cytarabine Small molecule 1500 mg/m2 Intravenous
Comparator Cytarabine Small molecule 2000 mg/m2 Intravenous
Subject Fludarabine Small molecule 30 mg/m2 Intravenous
Subject Fludarabine Small molecule 50 mg/m2 Intravenous